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Abstract 
Purpose: To investigate the therapeutic effects of "inhaled" roflumilast and formoterol separately or 
combined with fluticasone on the ultrastructural airway changes in ovalbumin-induced asthmatic mice. 
Methods: The asthmatic mice were divided randomly into seven groups (n = 8): positive control, 
vehicle, and five treated groups. The following treatments were given by inhalation (15 min once/day) 
for seven days: roflumilast (500 µg/kg), formoterol (50 µg/kg), fluticasone (1000 µg/kg), roflumilast + 
fluticasone (500 + 1000 µg/kg), and formoterol + fluticasone (50 + 1000 µg/kg). Ultrathin lung sections 
(50 - 70 nm thick) were examined by transmission electron microscopy. 
Results: The asthmatic mice showed marked degenerative changes in bronchiolar epithelial cells. The 
alveolar septal walls were thickened with cellular changes and capillary congestion. The basement 
membranes showed marked thickening and the airway lumens contained abundant mucinous 
secretions. These ovalbumin-induced ultrastructural airway changes were markedly-reversed in the 
roflumilast + fluticasone group, moderately-reversed in the roflumilast, fluticasone, and formoterol + 
fluticasone groups, but were not affected in the formoterol group.  
Conclusion: Co-inhalation of roflumilast + fluticasone significantly improved the ultrastructural airway 
changes than co-inhalation of formoterol + fluticasone in ovalbumin-asthmatic mice due to its anti-
inflammatory and antifibrotic effects.  
 
Keywords: Asthma, Fluticasone Propionate, Formoterol, Roflumilast, Ovalbumin, Remodeling, 
Bronchiolar epithelium 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




In bronchial asthma the injured airway epithelium 
enhances airway inflammation and remodeling 
through secretion of proinflammatory mediators 
[1]. Airway remodeling occurs partly as a result of 
chronic inflammation. It is manifested by 
epithelial changes, goblet cell hyperplasia, sub-
epithelial fibrosis, thickened smooth muscle 
layer, and increased vascularity. It leads to 
airway narrowing,  hyperresponsiveness, edema, 
progressive declining of lung functions, and more 
need for medications [2]. The airway smooth 
muscle also secretes inflammatory mediators 
and its mass increases due to hypertrophy, 
hyperplasia, and deposition of extracellular 
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matrix proteins [3]. In asthma, airway 
inflammation generally responds to treatments 
but unfortunately airway remodeling is resistant 
[4]. Inhaled corticosteroids (ICS) are the 
mainstay in asthma therapy; however, systemic 
side effects may occur at high doses [5].  
 
Formoterol is a long-acting β2 agonist (LABA) 
with rapid onset of bronchodilation. LABAs do not 
have  clinically important anti-inflammatory  
effects,  thus in treatment of asthma they are 
always combined with ICS [6]. Roflumilast is a 
selective phosphodiesterase (PDE) inhibitor 
which is approved as an add-on treatment for 
chronic obstructive pulmonary disease (COPD). 
PDE-4 inhibitors are ineffective bronchodilators 
but they are powerful anti-inflammatory agents 
[7]. In a recently-published work [8], it was 
concluded that co-inhalation of roflumilast and 
fluticasone significantly improved the 
inflammatory  and histopathological changes 
than that  of formoterol plus fluticasone in 
ovalbumin-asthmatic mice.  
 
Studying the ultrastructural changes at cellular 
and subcellular levels using transmission 
electron microscopy (TEM) reveals more details 
and hence helps more understanding of the 
effects of the different treatments especially the 
anti-remodeling effect. Consequently, the current 
study was designed in OVA-sensitized and 
challenged mice to investigate the therapeutic 
effects of inhaled roflumilast and formoterol 
separately or combined with fluticasone on the 






The study was carried out according to the 
International Guidelines for the Care and Use of 
Laboratory Animals [9]. The protocol was 
approved by the institutional Research Ethics 
Committee (ref no. 198-15). Drugs and 
chemicals were purchased from Sigma-Aldrich 
Corp. (St. Louis, MO, USA) unless mentioned 
otherwise. Female BALB/c mice (8 - 10 weeks 
old and about 30 g weight) were housed in cages 
at 24 °C in a 12 h light-dark cycle and were 
acclimatized for a week before experimentation. 
Animal feed and water were available ad libitum. 
 
Ovalbumin sensitization and challenge 
 
The mice were sensitized by intraperitoneal 
injection of 20 µg of ovalbumin (OVA) in 0.1 mL 
of Alum (aluminium hydroxide powder) on days 0 
and 14. The phosphate-buffered saline (PBS) 
was used as a vehicle for OVA. On days 27, 28, 
47, 61, and 73 - 75, mice were subjected to 





In addition to the normal control (NC) group 
(sensitized and challenged with PBS), the OVA-
sensitized and challenged mice were divided at 
random into seven groups (n = 8): positive 
control (PC) group (saline-treated), vehicle-
treated group, and five drug-treated groups. 
Drugs were given by inhalation for 15 min 
once/day for seven doses with the last dose 
given 5 - 6 h before the final OVA challenge. The 
drugs given included roflumilast (R, 500 µg/kg) 
[12], formoterol (Fo, 50 µg/kg) [10], fluticasone 
(F, 1000 µg/kg) [13, 14], roflumilast + fluticasone 
(R + F, 500+1000 µg/kg) and formoterol + 
fluticasone (Fo + F, 50 + 1000 µg/kg) [13, 15]. 
Dimethyl sulfoxide (DMSO) was used as a 
vehicle for the drugs. 
 
Transmission electron microscopy  
 
Mice were sacrificed by cervical dislocation. 
Immediately after animal dissection, lung 
specimens (1 - 2 mm3) were fixed in 2.5 % cold 
glutaraldehyde. Specimens were washed in 
cacodylate buffer (pH 7.2) three times (20 min 
each), post-fixed in 1 % osmium tetraoxide for 2 
h, dehydrated in rising  grades of ethanol, and 
embedded in Epon-araldite mixture. Semithin 
sections (1.0 µm thick) were cut from the 
embedded blocks, stained with toluidine blue, 
and then examined by light microscopy. The 
areas suitable for examination by electron 
microscopy were determined and ultrathin 
sections (50 – 70 nm thick) were obtained by the 
LKB ultramicrotome. The sections were stained 
with uranyl acetate and lead citrate. They were  
examined by transmission electron 
microscope (TEM) (100 CXII;JEOL, Ltd., 
Tokyo, Japan), and photomicrographed by a 




Data are expressed as mean ± SEM and 
were analysed with SPSS 18. Comparisons 
were made using Student's t-test for two 
groups and one-way analysis of variance 
(ANOVA) with Tukey’s test for more than two 





In the toluidine blue stained sections (Figure 1), 
TEM images of bronchioles and alveolar tissue 
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Figure 1: Micrographs of lung stained by toluidine blue (x200) in untreated and treated ovalbumin-asthmatic 
mice. (A) Normal control group showing that the bronchiolar wall formed by a thin fibrous layer and lined by 
Clara cells and few ciliated cells. The lumen (L) is free from secretions. The peribronchiolar alveoli show empty 
alveolar lumen (x). The alveolar septa are thin and formed by flattened elongated cells (pneumocyte type I) (1), 
few large cells (pneumocyte type II) (2), and septal capillaries (c). (B) Positive control: (B1, B2) group: [B1] 
showing marked degenerative changes of the bronchiolar epithelium. The lumen (L) contains abundant amounts 
of secretions (Se), [B2] showing that the alveolar septa are thickened and the population of pneumocyte type II 
(2) is increased with marked hypertrophy. The alveolar lumens (L) are mostly narrow. (C) Roflumilast group, (E) 
Fluticasone group, and (G) Formoterol + fluticasone group showing that the bronchioles have swollen Clara 
cells with deeply stained cytoplasmic granules. The ciliated cells are numerous and deeply stained. The 
bronchiolar wall is formed by a thin fibrous layer. The peribronchiolar alveoli show distention and their septal 
walls show a membranous structure (arrow), slight thickening, congestion of septal capillaries, and few 
pneumocytes (D) Formoterol group showing that the bronchiolar lining epithelium is formed from an increased 
population of Clara cells which appear faintly stained with deeply stained granules. The ciliated cells are 
compressed and embedded between Clara cells. The lumen (L) contains secretory material. The peribronchiolar 
alveoli show thickened septal wall and congestion of septal capillaries. The alveolar lumen contains faintly 
stained material and cellular debris (x). (F) Roflumilast + fluticasone group showing that the bronchiolar wall is 
formed by a thin fibrous wall and is lined by Clara cells containing deeply stained granules. The ciliated cells 
appear deeply stained, and embedded between Clara cells. The lumen (L) is empty. The alveolar septa are thin 
 
(Figure 2 and Figure 3), PC group showed 
marked ultrastructural changes as compared to 
NC group. These changes were markedly-
reversed in the roflumilast + fluticasone group 
and moderately-reversed in the roflumilast, 
fluticasone, and formoterol + fluticasone groups 
while not-reversed in the formoterol group. 
 
The increases in the airway basement 
membrane thickness and alveolar septal wall 
thickness were marked in the PC and formoterol 
groups, moderate in the roflumilast, fluticasone, 
and formoterol + fluticasone groups, and mild in 
the roflumilast + fluticasone group (Table 1). 
DISCUSSION 
 
In the current study, the asthmatic mice showed 
marked degenerative changes of bronchiolar 
epithelium cells. The alveolar septal walls were 
thickened with cellular changes and capillary 
congestion. The basement membranes showed 
marked thickening and the airway lumens 
contained abundant mucinous secretions. 
Previously, similar ultrastructural airway changes 
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Figure 2: Transmission electron microscopy (TEM) micrographs of lung bronchioles stained by uranyl acetate 
and lead citrate (x2900) in untreated and treated ovalbumin-asthmatic mice. (A) Normal control group: showing 
that the epithelial lining of the bronchiole is formed from few ciliated cells (Ci) and numerous Clara cells (Cc) 
which have large vesicular nuclei (N) and a large amount of cytoplasmic electron dense (Ed) secretory granules 
beside the cell organelles. Both types of cells are situated on the basement membrane (B). The bronchiolar wall 
is formed from a thin fibrous layer containing a capillary (C). (B)  Positive control group: showing swollen and 
sometimes ruptured Clara cells (Cc) and the electron dense (Ed) secretory granules are markedly reduced. The 
ciliated epithelial cells (Ci) appear compressed and more electron dense, and some of them contain numerous 
vacuoles (v). The lumen (L) contains light electron dense mucinous secretion. (C) Roflumilast group, (E) 
Fluticasone group, and (G) Formoterol + fluticasone group showing that Clara cells (Cc) contain moderate 
amount of electron dense (Ed) secretory granules, dilated rough endoplasmic reticulum (RER), and numerous 
large vacuoles (v). The ciliated cells (Ci) show numerous variable size electron dense (Ed) cytoplasmic bodies. 
The bronchiolar lumen contains a small amount of secretion (x). (D) Formoterol group showing swollen and 
vacuolated Clara cells (Cc) with marked reduction of the cytoplasmic electron dense (Ed) secretory granules and 
occasional pyknotic nuclei (N). The ciliated cells (Ci) are compressed with increased cytoplasmic electron 
density. (F)  Roflumilast + fluticasone group showing that the bronchiolar epithelium is formed from both Cc 
and Ci cells situated on the basement membrane. The Clara cells (Cc) contain large vesicular nuclei (N) and a 
large amount of cytoplasmic electron dense (Ed) secretory granules. The ciliated cells (Ci) are shorter with more 
electron dense cytoplasm and vesicular nuclei. The bronchiolar wall is formed from thin fibrous collagen layer 
(Co). Scale bar, 2 μm. 
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Figure 3: Transmission electron microscopy (TEM) micrographs of lung alveoli stained by uranyl acetate and 
lead citrate (x2900) in untreated and treated ovalbumin-asthmatic mice. (A) Normal control group: Alveolar 
cells include pneumocytes type I (1) and pneumocyte type II (2) which contains lamellar bodies (Lb), 
mitochondria (m), and large vesicular nuclei (N) with short luminal microvilli (arrow). Septalcapillary (C) contains 
RBCs, blood platelets (bp) and leukocytes (Le).  (B) Positive control (B1, B2, B3 groups): [B1] Hypertrophied 
pneumocytes type II (2) with large vesicular nuclei (N), numerous mitochondria (m), many lamellar bodies (Lb) 
and vacuoles (v), and few luminal microvilli (arrow), [B2] Markedly-thickened septal wall due to collagen (Co) and 
dilated septal capillary (c). Pneumocyte type I (1) contains numerous vacuoles (v). Alveolar lumen contains 
electron dense membranous structure (arrow), [B3] Markedly-thickened basement membrane (arrow). 
Pneumocyte type II (2) contains numerous lamellar bodies (Lb) or vacuoles (v). Alveolar lumen (L) contains 
cellular debris and secretions (x). (C) Roflumilast group, (E) Fluticasone group, and (G) Formoterol + 
fluticasone group: Alveolar septa contain capillaries (C), hypertrophied pneumocyte type II (2) containing large 
vesicular nuclei (N), few lamellar bodies (Lb), mitochondria (m), and free ribosomes. Pneumocyte type I (1) 
appears elongated and covered with electron dense membranous material (arrow). Alveolar lumen (L) is empty. 
(D) Formoterol group: thickened alveolar septa with collagen (Co) and congested septal capillaries (C). 
Hypertrophied pneumocytes type II (2) containing numerous lamellar bodies (Lb), moderate amount of 
mitochondria (m), and RER with surface microvilli (arrow). Pneumocyte type I (1) are flattened and covered with 
electron dense membranous threads (arrow). Alveolar lumen (L) contains small amount of light electron dense 
material. (F) Roflumilast + fluticasone group: Alveolar lumen (L) is empty and septal wall contains pneumocyte 
type II (2) which has a vesicular nucleus (N), mitochondria (m), and lamellar bodies (Lb) with luminal microvilli 
(arrow). Pneumocyte type I (1) is elongated. Septal wall contains collagen fiber (Co) and lymphocyte (Lc) with 
dilated septal capillary. Scale bar, 2 μm. 
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Table 1: Effects of treatments on the airway basement membrane thickness (nm) and alveolar septal wall 
thickness (µm) in ovalbumin-induced asthma in mice 
 












































Treatments (µg/kg/day by inhalation for 15 min for 7 days) included R (roflumilast, 500), Fo (formoterol, 50), F 
(fluticasone, 1000), R + F (roflumilast + fluticasone, 500+1000), and Fo + F (formoterol + fluticasone, 50 + 1000) 
(n=8). The image-pro plus software was used. Data are expressed as mean ± SEM. Comparisons were made 
using ANOVA with Tukey’s post-hoc test. †; p < 0.05: R + F vs. R & Fo + F  (p = 0.017 & 0.028 respectively), F 
vs. Fo (p = 0.010), ††; p < 0.01:  R, F, & Fo + F vs. PC (p = 0.002, 0.003, & 0.001 respectively), R & Fo + F vs. Fo 
(p = 0.005 & 0.003 respectively), R + F vs. F (p = 0.009), †††; p < 0.001:  all treatments (except R + F) vs. NC, R + 
F vs. PC & Fo. *; p < 0.05: F vs. Fo (p = 0.028), **; p < 0.01:  R vs. Fo (p = 0.002), R + F vs. R & Fo + F (p = 0.004 
& 0.002 respectively), Fo + F vs. Fo (p = 0.005), ***; p < 0.001:  all treatments (except R + F) vs. NC, all 
treatments (except Fo) vs. PC, R + F vs. Fo & F. 
 
The numbers of Clara cells and ciliated epithelial 
cells decreased while the numbers of goblet cells 
increased with numerous secretory granules 
containing mucus. The basement membrane was 
thickened due to deposition of collagen.   The 
myofibroblast sheath was also thickened due to 
high content of collagen and myofibroblasts in 
addition to smooth muscle hypertrophy and 
hyperplasia. The bronchial epithelium was 
shrunken with pyknotic nuclei. Moreover, there 
were platelet activation and inflammatory cell 
infiltration in the perivascular and peribronchiolar 
areas. In the airway smooth muscle, the 
mitohcondria increased in number with 
ultrastructural changes.  . In another study in 
OVA -sensitized and -challenged mice, changes 
of the epithelial phenotype were detected 
especially in the proximal airways.   The toluidine 
blue-stained sections showed a significant 
increase in goblet cells which completely 
compensated the significant decrease in Clara 
cells and the non-significant decrease of ciliated 
cells. Consequently, the epithelial thickness 
significantly increased due to replacement of the 
smaller Clara cells by the larger mucous cells 
(mucous cell metaplasia). In the distal airways, 
there were no significant differences regarding  
the total number of epithelial cells per unit area 
of the basement membrane, the  thickness of 
epithelium, and  the different cell types [16]. In 
another study, the EM examination of biopsies 
obtained by fibreoptic endoscopy showed that 
airway myositis was characterized by a direct 
interaction between airway smooth muscle cells, 
mast cells, and lymphocytes. The smooth 
muscle remodeling was manifested by  muscle 
cell hypertrophy and abnormal extracellular 
matrix deposition [18]. 
 
The current results showed that the ovalbumin-
induced ultrastructural airway changes were 
markedly-reversed in the roflumilast + fluticasone 
group, moderately-reversed in the roflumilast, 
fluticasone, and formoterol + fluticasone groups, 
while not-reversed in the formoterol group. 
Previously it was found that ICS have a little 
effect on airway remodeling in vivo as shown by 
failure to decrease collagen deposition in lungs 
of asthmatic patients which may be due to 
inability to inhibit TGF-β1 expression [19]. 
Moreover, in OVA-sensitized rats, concomitant 
inhalation of fluticasone during OVA exposure 
partly inhibits airway remodeling and 
hyperresponsiveness while its inhalation after 
OVA exposure had no effect on remodeling [20]. 
Fortunately, roflumilast was found to decrease 
airway inflammation, deposition of subepithelial 
collagen, and epithelial thickening in a murine 
model of asthma [21]. In addition, oral roflumilast 
effectively reduced bleomycin-induced lung α-I 
collagen transcripts and fibrosis in both 
preventive and therapeutic protocols in rodents 
while oral glucocorticoids were ineffective in the 
therapeutic protocol [22].    
 
Failure of long acting β2 agonists (formoterol) to 
improve remodeling in the current study agrees 
with a previous study which showed that in OVA 
-sensitized and -challenged BALB/c mice, LABA 
treatment (salmeterol) exaggerated airway 
inflammation, remodeling, and hyperresponsive-
ness due to mucus metaplasia, while  fluticasone 
separately  or combined with salmeterol reduced 
airway inflammation and remodeling 
[10].Moreover, aerosolized combined salmeterol 
and fluticasone in rats reversed goblet cell 
hyperplasia, but increased fibronectin and 
collagen in the airway wall [23]. In addition, in 
asthmatic patients adding salmeterol to ICS 
reduced airway muscular tone and improved 
expiratory flows, but exerted a little effect on 
remodeling shown by decreasing number of 
vessels in the airway lamina propria [24]. 
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Co-inhalation of roflumilast and fluticasone 
significantly improved the ultrastructural airway 
changes than co-inhalation of formoterol and 
fluticasone in ovalbumin-asthmatic mice. This 
highlights the importance of adding roflumilast to 
fluticasone in asthma therapy due to its beneficial 
anti-inflammatory and antifibrotic effects. Due to 
species variations in the airway epithelium where 
most remodeling changes occur, the conclusions 
from this study cannot be readily extrapolated to 
human. Thus, clinical studies are recommended 
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